The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

January 09, 2020

Maria Chaudhry, MBBS, discusses unmet needs in relapsed/refractory multiple myeloma.

January 08, 2020

Jennifer A. Woyach, MD, discusses the evolving treatment paradigm and sequencing challenges in chronic lymphocytic leukemia.

January 08, 2020

David O’Malley, MD, discusses remaining questions in the ovarian cancer field.

January 07, 2020

Maria Chaudhry, MBBS, discusses recent and ongoing research in newly diagnosed and relapsed/refractory multiple myeloma.

January 07, 2020

Maria Chaudhry, MBBS, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone in transplant-ineligible patients with multiple myeloma.

January 07, 2020

Jennifer Woyach, MD, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia.

January 03, 2020

Jennifer Woyach, MD, discusses frontline treatment options for patients with chronic lymphocytic leukemia.

January 01, 2020

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

December 16, 2019

Casey M. Cosgrove, MD, discusses later-line treatments in ovarian cancer and ongoing research.

December 11, 2019

John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.

November 22, 2019

Ritu Salani, MD, discusses considerations for neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.

November 22, 2019

John Hays, MD, PhD, discusses ongoing research with immunotherapy in ovarian cancer, challenges with determining predictive biomarkers of response, and promising emerging modalities.

November 21, 2019

Larry J. Copeland, MD, discusses how therapy for patients with ovarian cancer has evolved in recent years.

November 21, 2019

Ritu Salani, MD, discusses the potential of targeted therapy and immunotherapy in cervical cancer.

November 21, 2019

Experts from The Ohio State University and Allegheny Health Network discuss the exciting research being conducted at their institutions.

November 20, 2019

Ritu Salani, MD, discusses the evolution of up-front chemotherapy, as well as the roles of primary debulking surgery and neoadjuvant chemotherapy in ovarian cancer.

November 19, 2019

David O’Malley, MD, discusses clinical trials in ovarian cancer and others under investigation.

November 12, 2019

Floor J. Backes, MD, discusses the safety profile from a phase I study looking at lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

November 12, 2019

Casey M. Cosgrove, MD, discusses factors to consider when selecting a PARP inhibitor as maintenance therapy in advanced ovarian cancer.

November 09, 2019

Leigha Senter, MS, LGC, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer.